glp-1 receptor agonists effects on cardiovascular risk reduction benefits of glucagon-like peptide-1 GLP-1 receptor agonist-based therapies and
Description
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

British Journal of Pharmacology, 39 (1), 16.

This guide will help

Journal of Nutrition Sciences
It does not have long-term safety data
